Skip to content

Chronic Lymphoid Leukaemia Observatory in Finistere Area, France

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03294980
Acronym
OFICE
Enrollment
3000
Registered
2017-09-27
Start date
2015-11-30
Completion date
2025-11-30
Last updated
2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphoid Leukaemia

Keywords

Chronic lymphocytic leukemia, Observational study

Brief summary

Brief Summary: The purpose of the OFICE registry is to characterize and describe the CLL patients' population from the Finistere area and evaluates the association between different patient characteristics, prognosis and treatment patterns. Detailed Description: OFICE is a single center, prospective, observational registry of CLL patients designed to provide a general description of the CLL patients' population from the Finistere area, France. The registry will also provide information on the association of cytogenetic and immunophenotypic characteristics with disease progression, as well as treatment patterns and healthcare resource utilization. These data will be accessible and beneficial for researchers and physicians and will help guide clinical practice and future clinical or fundamental studies.

Interventions

None listed

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age of at least 18 years * Clinical diagnosis of CLL/SLL that meets published diagnostic criteria (Hallek 2008) * Willing and able to provide informed consent * Willing and able to provide blood sample at time of enrollment

Exclusion criteria

* Diagnosis of other B-cell malignancies

Design outcomes

Primary

MeasureTime frameDescription
PrevalenceYear 0 (Y)Clinical data

Secondary

MeasureTime frameDescription
IncidenceYear 0Clinical and biological data
Description of baseline clinical-biologicalYear 0, Year 1, Year 2, Year 3Clinical data, complete blood count, Matutes score and parameters, cytogenetic, IgVH mutations, CD38 (%), medical treatment will be collected

Countries

France

Contacts

Primary ContactYves Renaudineau
yves.renaudineau@chu-brest.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026